Related Experiment Video

Updated: May 5, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.9K

Direct acting antivirals for the treatment of chronic viral hepatitis

Peter Karayiannis1

  • 1Section of Hepatology and Gastroenterology, Department of Medicine, Imperial College, St Mary's Campus, London W2 1PG, UK.

Scientifica
|November 27, 2013
PubMed

Insights

Antiviral therapies have transformed hepatitis C (HCV) and hepatitis B (HBV) treatment, enabling viral suppression and sustained responses. However, significant progress in treating hepatitis D (HDV) remains limited, highlighting an unmet clinical need.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic viral hepatitis, including hepatitis B (HBV), C (HCV), and D (HDV) infections, poses a significant global health burden.
  • Antiviral drug development has revolutionized HBV and HCV treatment over the past 25 years.
  • Hepatitis D virus (HDV) treatment has lagged significantly behind HBV and HCV, with limited therapeutic breakthroughs.

Purpose of the Study:

  • To review current treatment strategies for chronic viral hepatitis (HBV, HCV, HDV).
  • To discuss the advancements in antiviral therapies for HBV and HCV.
  • To highlight the challenges and future perspectives in managing HDV infection.

Main Methods:

  • Review of clinical trial data and published literature on antiviral agents for HBV, HCV, and HDV.
  • Analysis of treatment outcomes, including viral suppression and sustained virological responses (SVRs).
  • Comparative assessment of therapeutic progress across HBV, HCV, and HDV.

Main Results:

  • Direct-acting antivirals (DDAs) allow long-term suppression of HBV replication.
  • HCV treatment, often with pegylated interferon (PegIFN) and ribavirin, achieves SVRs with increasing success.
  • Significant therapeutic advancements for HDV infection are still lacking.

Conclusions:

  • Effective antiviral treatments are available for chronic HBV and HCV, significantly improving patient outcomes.
  • The lack of progress in HDV treatment underscores the urgent need for novel therapeutic approaches.
  • Future research should focus on developing effective therapies for HDV to address this critical unmet medical need.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K